Chemicals - Specialty
Build Your Comparison
Side-by-side financial analysisStock Comparison
PRM vs IOSP vs ASIX vs JPM vs BCPC
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
Chemicals
Banks - Diversified
Chemicals - Specialty
PRM vs IOSP vs ASIX vs JPM vs BCPC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty | Chemicals | Banks - Diversified | Chemicals - Specialty |
| Market Cap | $5.79B | $2.13B | $615M | $896.00B | $5.29B |
| Revenue (TTM) | $706M | $1.79B | $1.55B | $280.33B | $1.06B |
| Net Income (TTM) | $-190M | $114M | $10M | $57.05B | $158M |
| Gross Margin | 56.4% | 27.4% | 7.4% | 60.0% | 36.3% |
| Operating Margin | -20.5% | 8.1% | 0.7% | 25.9% | 21.0% |
| Forward P/E | 20.3x | 17.9x | 15.9x | 14.4x | 31.5x |
| Total Debt | $34M | $90M | $383M | $942.38B | $192M |
| Cash & Equiv. | $326M | $293M | $20M | $343.34B | $75M |
PRM vs IOSP vs ASIX vs JPM vs BCPC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Nov 21 | Jun 26 | Return |
|---|---|---|---|
| Perimeter Solutions… (PRM) | 100 | 301.9 | +201.9% |
| Innospec Inc. (IOSP) | 100 | 106.6 | +6.6% |
| AdvanSix Inc. (ASIX) | 100 | 50.4 | -49.6% |
| JPMorgan Chase & Co. (JPM) | 100 | 201.9 | +101.9% |
| Balchem Corporation (BCPC) | 100 | 104.5 | +4.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRM vs IOSP vs ASIX vs JPM vs BCPC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PRM has the current edge in this matchup, primarily because of its strength in growth and momentum.
- 16.4% revenue growth vs IOSP's -3.7%
- +164.1% vs ASIX's -4.2%
IOSP is the clearest fit if your priority is valuation efficiency.
- PEG 0.56 vs ASIX's 8.46
ASIX is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 0.59, yield 2.8%
- Beta 0.59, yield 2.8%, current ratio 1.13x
- 2.8% yield, vs BCPC's 0.5%, (1 stock pays no dividend)
JPM is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 465.8% 10Y total return vs PRM's 195.6%
- Lower P/E (14.4x vs 31.5x), PEG 0.81 vs 2.46
- 20.4% margin vs PRM's -26.9%
BCPC ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.
- Rev growth 8.8%, EPS growth 20.9%, 3Y rev CAGR 3.2%
- Lower volatility, beta 0.26, Low D/E 15.3%, current ratio 2.07x
- Beta 0.26 vs PRM's 1.09
- 9.4% ROA vs PRM's -6.9%, ROIC 12.2% vs -11.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 16.4% revenue growth vs IOSP's -3.7% | |
| Value | Lower P/E (14.4x vs 31.5x), PEG 0.81 vs 2.46 | |
| Quality / Margins | 20.4% margin vs PRM's -26.9% | |
| Stability / Safety | Beta 0.26 vs PRM's 1.09 | |
| Dividends | 2.8% yield, vs BCPC's 0.5%, (1 stock pays no dividend) | |
| Momentum (1Y) | +164.1% vs ASIX's -4.2% | |
| Efficiency (ROA) | 9.4% ROA vs PRM's -6.9%, ROIC 12.2% vs -11.6% |
PRM vs IOSP vs ASIX vs JPM vs BCPC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PRM vs IOSP vs ASIX vs JPM vs BCPC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
JPM leads in 1 of 6 categories
ASIX leads 1 • BCPC leads 1 • PRM leads 1 • IOSP leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
JPM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM is the larger business by revenue, generating $280.3B annually — 397.1x PRM's $706M. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to PRM's -26.9%. On growth, PRM holds the edge at +73.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $706M | $1.8B | $1.5B | $280.3B | $1.1B |
| EBITDAEarnings before interest/tax | -$102M | $187M | $93M | $81.4B | $267M |
| Net IncomeAfter-tax profit | -$190M | $114M | $10M | $57.0B | $158M |
| Free Cash FlowCash after capex | $86M | $77M | -$22M | $100.9B | $182M |
| Gross MarginGross profit ÷ Revenue | +56.4% | +27.4% | +7.4% | +60.0% | +36.3% |
| Operating MarginEBIT ÷ Revenue | -20.5% | +8.1% | +0.7% | +25.9% | +21.0% |
| Net MarginNet income ÷ Revenue | -26.9% | +6.4% | +0.7% | +20.4% | +15.0% |
| FCF MarginFCF ÷ Revenue | +12.2% | +4.3% | -1.4% | +36.0% | +17.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +73.6% | +2.8% | +7.0% | — | +8.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +22.2% | -6.9% | -167.4% | +16.0% | +10.6% |
Valuation Metrics
ASIX leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 12.7x trailing earnings, ASIX trades at a 64% valuation discount to BCPC's 34.7x P/E. Adjusting for growth (PEG ratio), IOSP offers better value at 0.58x vs ASIX's 6.74x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $5.8B | $2.1B | $615M | $896.0B | $5.3B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $1.9B | $978M | $1.50T | $5.4B |
| Trailing P/EPrice ÷ TTM EPS | -25.89x | 18.54x | 12.67x | 16.00x | 34.75x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.34x | 17.93x | 15.90x | 14.40x | 31.52x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.58x | 6.74x | 0.90x | 2.71x |
| EV / EBITDAEnterprise value multiple | — | 9.39x | 6.64x | 18.36x | 20.50x |
| Price / SalesMarket cap ÷ Revenue | 8.86x | 1.20x | 0.40x | 3.20x | 5.10x |
| Price / BookPrice ÷ Book value/share | 4.66x | 1.62x | 0.76x | 2.47x | 4.28x |
| Price / FCFMarket cap ÷ FCF | 27.74x | 24.24x | 95.81x | 8.88x | 30.54x |
Profitability & Efficiency
BCPC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-16 for PRM. PRM carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), BCPC scores 9/9 vs JPM's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -16.4% | +8.6% | +1.3% | +15.9% | +12.4% |
| ROA (TTM)Return on assets | -6.9% | +6.3% | +0.6% | +1.3% | +9.4% |
| ROICReturn on invested capital | -11.6% | +11.2% | +4.4% | +4.5% | +12.2% |
| ROCEReturn on capital employed | -8.3% | +11.0% | +5.3% | +8.9% | +14.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 6 | 5 | 9 |
| Debt / EquityFinancial leverage | 0.03x | 0.07x | 0.47x | 2.60x | 0.15x |
| Net DebtTotal debt minus cash | -$292M | -$203M | $363M | $599.0B | $117M |
| Cash & Equiv.Liquid assets | $326M | $293M | $20M | $343.3B | $75M |
| Total DebtShort + long-term debt | $34M | $90M | $383M | $942.4B | $192M |
| Interest CoverageEBIT ÷ Interest expense | -5.17x | — | 1.38x | 0.74x | 15.23x |
Total Returns (Dividends Reinvested)
PRM leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRM five years ago would be worth $29,558 today (with dividends reinvested), compared to $8,730 for ASIX. Over the past 12 months, PRM leads with a +164.1% total return vs ASIX's -4.2%. The 3-year compound annual growth rate (CAGR) favors PRM at 78.1% vs ASIX's -11.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +28.9% | +14.7% | +34.3% | -0.5% | +7.2% |
| 1-Year ReturnPast 12 months | +164.1% | +1.4% | -4.2% | +21.8% | +1.3% |
| 3-Year ReturnCumulative with dividends | +464.8% | -7.8% | -30.0% | +138.2% | +24.7% |
| 5-Year ReturnCumulative with dividends | +195.6% | -4.2% | -12.7% | +118.2% | +27.7% |
| 10-Year ReturnCumulative with dividends | +195.6% | +105.2% | +54.4% | +465.8% | +180.9% |
| CAGR (3Y)Annualised 3-year return | +78.1% | -2.7% | -11.2% | +33.6% | +7.6% |
Risk & Volatility
Evenly matched — PRM and BCPC each lead in 1 of 2 comparable metrics.
Risk & Volatility
BCPC is the less volatile stock with a 0.26 beta — it tends to amplify market swings less than PRM's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRM currently trades 98.5% from its 52-week high vs ASIX's 85.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | 0.70x | 0.59x | 0.94x | 0.26x |
| 52-Week HighHighest price in past year | $36.01 | $92.14 | $26.73 | $337.25 | $183.90 |
| 52-Week LowLowest price in past year | $13.05 | $65.58 | $14.10 | $262.71 | $139.17 |
| % of 52W HighCurrent price vs 52-week peak | +98.5% | +94.0% | +85.3% | +95.1% | +89.7% |
| RSI (14)Momentum oscillator 0–100 | 66.7 | 71.7 | 42.7 | 59.1 | 59.1 |
| Avg Volume (50D)Average daily shares traded | 1.2M | 176K | 269K | 7.0M | 171K |
Analyst Outlook
Evenly matched — ASIX and BCPC each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PRM as "Buy", IOSP as "Hold", ASIX as "Buy", JPM as "Buy", BCPC as "Buy". Consensus price targets imply 32.8% upside for IOSP (target: $115) vs -3.6% for ASIX (target: $22). For income investors, ASIX offers the higher dividend yield at 2.76% vs BCPC's 0.53%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $37.00 | $115.00 | $22.00 | $339.75 | $175.50 |
| # AnalystsCovering analysts | 2 | 9 | 6 | 61 | 10 |
| Dividend YieldAnnual dividend ÷ price | — | +2.0% | +2.8% | +1.9% | +0.5% |
| Dividend StreakConsecutive years of raises | 0 | 12 | 0 | 15 | 16 |
| Dividend / ShareAnnual DPS | — | $1.70 | $0.63 | $5.95 | $0.87 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.7% | 0.0% | +0.3% | +3.9% | +2.0% |
JPM leads in 1 of 6 categories (Income & Cash Flow). ASIX leads in 1 (Valuation Metrics). 2 tied.
PRM vs IOSP vs ASIX vs JPM vs BCPC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PRM or IOSP or ASIX or JPM or BCPC a better buy right now?
For growth investors, Perimeter Solutions, S.
A. (PRM) is the stronger pick with 16. 4% revenue growth year-over-year, versus -3. 7% for Innospec Inc. (IOSP). AdvanSix Inc. (ASIX) offers the better valuation at 12. 7x trailing P/E (15. 9x forward), making it the more compelling value choice. Analysts rate Perimeter Solutions, S. A. (PRM) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRM or IOSP or ASIX or JPM or BCPC?
On trailing P/E, AdvanSix Inc.
(ASIX) is the cheapest at 12. 7x versus Balchem Corporation at 34. 7x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innospec Inc. wins at 0. 56x versus AdvanSix Inc. 's 8. 46x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — PRM or IOSP or ASIX or JPM or BCPC?
Over the past 5 years, Perimeter Solutions, S.
A. (PRM) delivered a total return of +195. 6%, compared to -12. 7% for AdvanSix Inc. (ASIX). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ASIX's +54. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRM or IOSP or ASIX or JPM or BCPC?
By beta (market sensitivity over 5 years), Balchem Corporation (BCPC) is the lower-risk stock at 0.
26β versus Perimeter Solutions, S. A. 's 1. 09β — meaning PRM is approximately 311% more volatile than BCPC relative to the S&P 500. On balance sheet safety, Perimeter Solutions, S. A. (PRM) carries a lower debt/equity ratio of 3% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.
05Which is growing faster — PRM or IOSP or ASIX or JPM or BCPC?
By revenue growth (latest reported year), Perimeter Solutions, S.
A. (PRM) is pulling ahead at 16. 4% versus -3. 7% for Innospec Inc. (IOSP). On earnings-per-share growth, the picture is similar: Innospec Inc. grew EPS 228. 9% year-over-year, compared to -32. 8% for Perimeter Solutions, S. A.. Over a 3-year CAGR, PRM leads at 21. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRM or IOSP or ASIX or JPM or BCPC?
JPMorgan Chase & Co.
(JPM) is the more profitable company, earning 20. 4% net margin versus -31. 6% for Perimeter Solutions, S. A. — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -30. 8% for PRM. At the gross margin level — before operating expenses — JPM leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRM or IOSP or ASIX or JPM or BCPC more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Innospec Inc. (IOSP) is the more undervalued stock at a PEG of 0. 56x versus AdvanSix Inc. 's 8. 46x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 4x forward P/E versus 31. 5x for Balchem Corporation — 17. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IOSP: 32. 8% to $115. 00.
08Which pays a better dividend — PRM or IOSP or ASIX or JPM or BCPC?
In this comparison, ASIX (2.
8% yield), IOSP (2. 0% yield), JPM (1. 9% yield), BCPC (0. 5% yield) pay a dividend. PRM does not pay a meaningful dividend and should not be held primarily for income.
09Is PRM or IOSP or ASIX or JPM or BCPC better for a retirement portfolio?
For long-horizon retirement investors, Balchem Corporation (BCPC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
26), 0. 5% yield, +180. 9% 10Y return). Both have compounded well over 10 years (BCPC: +180. 9%, PRM: +195. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRM and IOSP and ASIX and JPM and BCPC?
These companies operate in different sectors (PRM (Basic Materials) and IOSP (Basic Materials) and ASIX (Basic Materials) and JPM (Financial Services) and BCPC (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: PRM is a small-cap high-growth stock; IOSP is a small-cap quality compounder stock; ASIX is a small-cap deep-value stock; JPM is a large-cap deep-value stock; BCPC is a small-cap quality compounder stock. IOSP, ASIX, JPM, BCPC pay a dividend while PRM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.